Thank you for subscribing!
Finfeed Feb 18, 2022
Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.
Next Investors Feb 18, 2022
Finfeed Archived Apr 01, 2020
ImpediMed Limited (ASX: IPD) has received the first order of 16 units under the recently announced national purchasing agreement with a US oncology care network for its SOZO® Digital Health Platform and Lymphoedema Prevention Program.
Next Investors Archived Nov 07, 2019
One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.
Get expert stock analysis direct in your inbox
Next Investors Archived Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
Finfeed Archived Jun 12, 2019
Immuron Ltd (ASX:IMC; NASDQ:IMRN), has provided an extremely promising update on the company’s cooperative research and development agreements with the US Department of Defence, no doubt contributing to its strong share price performance on the back of this news.
Finfeed Archived Apr 08, 2019
Genetic Technologies Ltd (ASX:GTG), a provider of world-leading genetic risk assessment test products, has established an important MoU with TGen, a major player in the US biomedical research industry.
Finfeed Archived Mar 21, 2019
Imugene Limited (ASX:IMU) has now received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy.
Next Investors Archived Jan 31, 2019
Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.
Finfeed Archived Jan 07, 2019
Imugene (ASX:IMU) has appointed world-renowned cancer researcher, Professor Michael Caligiuri — President of the City of Hope National Medical Center in LA — to its Scientific Advisory Board (SAB).
Join Our Mailing List
